Alterations in the oral microbiome in HIV-infected participants after antiretroviral therapy administration are influenced by immune status
-
Quality control
- Retracted paper
- Contamination issues suspected
- Batch effect issues suspected
- Uncontrolled confounding suspected
- Results are suspect (various reasons)
- Tags applied
Experiment 1
Subjects
- Location of subjects
- United States of America
- Host species Species from which microbiome was sampled. Contact us to have more species added.
- Homo sapiens
- Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
- Saliva Sailva normalis,Saliva atomaris,Saliva molecularis,Salivary gland secretion,Saliva,saliva
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Viral load viral burden,viral titer,viral titre,Viral load,viral load
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- High viral load at baseline
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Low viral load at baseline
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Participants with viral load less than 100 000 copies/ml at baseline
- Group 0 sample size Number of subjects in the control (unexposed) group
- 9
- Group 1 sample size Number of subjects in the case (exposed) group
- 26
- Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
- N/A
Lab analysis
- Sequencing type
- 16S
- 16S variable region One or more hypervariable region(s) of the bacterial 16S gene
- V4
- Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
- Illumina
Statistical Analysis
- Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
- relative abundances
- Statistical test
- Mann-Whitney (Wilcoxon)
- Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
- 0.05
- MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
- Yes
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Experiment 2
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- Response to antiviral drug Response to antiviral drug,response to antiviral drug
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Baseline samples
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Week 24 samples
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Saliva samples after 24 weeks of antiretroviral therapy
- Group 0 sample size Number of subjects in the control (unexposed) group
- 35
- Group 1 sample size Number of subjects in the case (exposed) group
- 35
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure 2 :Table S1
Description: Bacterial taxa differentially abundant in saliva prior to and following 24 weeks of antiretroviral therapy
Abundance in Group 1: increased abundance in Week 24 samples
NCBI | Quality Control | Links |
---|---|---|
Treponema lecithinolyticum |
Revision editor(s): MyleeeA
Signature 2
Source: Figure 2, Table S1
Description: Bacterial taxa differentially abundant in saliva prior to and following 24 weeks of antiretroviral therapy
Abundance in Group 1: decreased abundance in Week 24 samples
NCBI | Quality Control | Links |
---|---|---|
Muribaculum intestinale |
Experiment 3
Subjects
- Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
- CD4-positive T-lymphocyte count CD4-positive T-lymphocyte count,cD4-positive T-lymphocyte count
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- Baseline CD4+ low samples
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- Baseline CD4+ high samples
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- Baseline CD4+ high samples before administering Anti Retroviral Therapy
Lab analysis
Statistical Analysis
- Statistical test
- Kruskall-Wallis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- unchanged
- Richness Number of species
- unchanged
Signature 1
Source: Figure 3, Table S2
Description: The effect of CD4+ T-cell counts on the salivary bacterial microbiome: Differential abundance of bacterial taxa in CD4+ low vs. CD4+ high patient saliva.
Abundance in Group 1: increased abundance in Baseline CD4+ high samples
NCBI | Quality Control | Links |
---|---|---|
Haemophilus parainfluenzae |
Experiment 4
Subjects
- Group 0 name Corresponds to the control (unexposed) group for case-control studies
- week 24 CD4+ low samples
- Group 1 name Corresponds to the case (exposed) group for case-control studies
- week 24 CD4+ high samples
- Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
- samples with high CD4+ at Week 24 following Anti Retroviral Therapy
Lab analysis
Statistical Analysis
Alpha Diversity
- Shannon Estimator of species richness and species evenness: more weight on species richness
- decreased
- Richness Number of species
- decreased
Signature 1
Source: Figure 3, Table S2
Description: The effect of CD4+ T-cell counts on the salivary bacterial microbiome: Differential abundance of bacterial taxa in CD4+ low vs. CD4+ high patient saliva.
Abundance in Group 1: decreased abundance in week 24 CD4+ high samples
NCBI | Quality Control | Links |
---|---|---|
Haemophilus parainfluenzae |